December 30, 2016 / 8:26 AM / 7 months ago

BRIEF-MPI and Oncology Venture in exclusivity and ownership agreements of SPVs

1 Min Read

Dec 30 (Reuters) - Medical Prognosis Institute A/S

* MPI and Oncology Venture enters exclusivity and ownership agreements of special purpose vehicles - financing secured for the first two special purpose vehicles

* MPI grants Oncology Venture three year world-wide exclusivity to MPI drug response prediction technology which Oncology Venture will use for drug development

* In return for extended exclusive license MPI is to receive warrants entitling to subscription of shares in Oncology Venture at price of 10 Swedish crowns ($1.10) per share

* Furthermore Oncology Venture and MPI agree to convert Oncology Venture license payment to MPI in relation to projects spun out to special purpose vehicles Source text for Eikon: Further company coverage: ($1 = 9.1046 Swedish crowns) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below